Paper Details

  1. Home
  2. Paper Details

Use of alpha-interferon in the treatment of chronic delta hepatitis.

Author: HadziyannisS J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This review examines the treatment of chronic delta hepatitis, a serious liver infection with limited treatment options. While alpha-interferon (alpha-IFN) can temporarily improve liver function, its effects are not long-lasting. Analysis of five studies showed that alpha-IFN significantly normalized liver enzymes during treatment, but did not maintain these improvements after stopping treatment. The optimal treatment schedule appears to be a higher dose of alpha-IFN (5 MU daily or 9 MU three times a week) for at least a year, leading to remission in 50-70% of patients. However, no factors have been identified that predict response to alpha-IFN, and no alternative treatments are currently available. Further research is needed to develop more effective therapies for chronic delta hepatitis.
Paper Details　
Original Abstract of the Article :
Chronic delta hepatitis is a severe disease with a rapidly progressive course for which currently no effective treatment exists. Treatment with alpha-interferon (alpha-IFN) can inhibit HDV replication and improve serum chemistries in a number of patients. Meta-analysis of five randomized controlled ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0168-8278(91)91716-t

データ提供：米国国立医学図書館（NLM）

Alpha-Interferon: A Beacon of Hope for Chronic Delta Hepatitis

Chronic delta hepatitis, a severe liver infection, is a formidable foe, often leading to rapid disease progression. This study examines the potential of alpha-interferon (alpha-IFN) as a treatment for this challenging condition. The study reviews multiple clinical trials, highlighting the potential benefits of alpha-IFN in suppressing HDV replication and improving liver function. This research is like finding a hidden oasis in the desert of hepatitis treatments, offering a potential path to recovery.

Alpha-Interferon: A Powerful Tool

The study suggests that alpha-IFN can effectively normalize ALT values, a key indicator of liver damage, in patients with chronic delta hepatitis. However, the study also notes that the effectiveness of alpha-IFN is often temporary. This discovery, like finding a temporary oasis in a desolate landscape, reminds us that ongoing treatment and monitoring are crucial for managing this complex condition.

Navigating the Desert of Hepatitis

This research provides valuable insights into the potential of alpha-IFN as a treatment option for chronic delta hepatitis. It highlights the need for long-term treatment strategies and continued research into more effective therapies.

Dr. Camel's Conclusion

This research offers a glimmer of hope for individuals battling chronic delta hepatitis. While alpha-IFN is a promising treatment option, further research is needed to develop more effective and lasting therapies.

Date :
  1. Date Completed 1992-01-07
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

1835731

DOI: Digital Object Identifier

10.1016/0168-8278(91)91716-t

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.